Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts. more
Time Frame | CUE | Sector | S&P500 |
---|---|---|---|
1-Week Return | -14.55% | -2.27% | -0.57% |
1-Month Return | -37.33% | -3.96% | 1.21% |
3-Month Return | 59.59% | -9.7% | 7.57% |
6-Month Return | -38.96% | -3.37% | 11.45% |
1-Year Return | -68.03% | 3.71% | 28.48% |
3-Year Return | -91.87% | 3.8% | 29.52% |
5-Year Return | -93.07% | 39.78% | 90.66% |
10-Year Return | -91.92% | 106.91% | 203.75% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 3.46M | 3.15M | 14.94M | 1.25M | 5.49M | [{"date":"2019-12-31","value":23.14,"profit":true},{"date":"2020-12-31","value":21.11,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":8.33,"profit":true},{"date":"2023-12-31","value":36.74,"profit":true}] |
Cost of Revenue | 27.49M | 33.55M | (1.78M) | 1.81M | 38.10M | [{"date":"2019-12-31","value":72.15,"profit":true},{"date":"2020-12-31","value":88.05,"profit":true},{"date":"2021-12-31","value":-4.67,"profit":false},{"date":"2022-12-31","value":4.74,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | 3.46M | (30.39M) | 14.94M | (560.83K) | (32.61M) | [{"date":"2019-12-31","value":23.14,"profit":true},{"date":"2020-12-31","value":-203.4,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-3.75,"profit":false},{"date":"2023-12-31","value":-218.23,"profit":false}] |
Gross Margin | 100.00% | (963.48%) | 100.00% | (45.04%) | (593.93%) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-963.48,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-45.04,"profit":false},{"date":"2023-12-31","value":-593.93,"profit":false}] |
Operating Expenses | 40.23M | 48.20M | 58.65M | 54.75M | 19.54M | [{"date":"2019-12-31","value":68.58,"profit":true},{"date":"2020-12-31","value":82.17,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":93.34,"profit":true},{"date":"2023-12-31","value":33.32,"profit":true}] |
Operating Income | (36.77M) | (45.04M) | (43.71M) | (53.22M) | (52.15M) | [{"date":"2019-12-31","value":-3676900000,"profit":false},{"date":"2020-12-31","value":-4504258500,"profit":false},{"date":"2021-12-31","value":-4371207300,"profit":false},{"date":"2022-12-31","value":-5322480900,"profit":false},{"date":"2023-12-31","value":-5214900000,"profit":false}] |
Total Non-Operating Income/Expense | 901.71K | 927.83K | 91.80K | 429.43K | 2.83M | [{"date":"2019-12-31","value":31.84,"profit":true},{"date":"2020-12-31","value":32.76,"profit":true},{"date":"2021-12-31","value":3.24,"profit":true},{"date":"2022-12-31","value":15.16,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (36.29M) | (44.58M) | (43.67M) | (53.01M) | (50.73M) | [{"date":"2019-12-31","value":-3628600000,"profit":false},{"date":"2020-12-31","value":-4457867100,"profit":false},{"date":"2021-12-31","value":-4366617500,"profit":false},{"date":"2022-12-31","value":-5301038200,"profit":false},{"date":"2023-12-31","value":-5073300000,"profit":false}] |
Income Taxes | 412.00K | 206.25K | 495.00K | (214.43K) | 3.27M | [{"date":"2019-12-31","value":12.61,"profit":true},{"date":"2020-12-31","value":6.31,"profit":true},{"date":"2021-12-31","value":15.15,"profit":true},{"date":"2022-12-31","value":-6.56,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Income After Taxes | (36.70M) | (44.78M) | (44.16M) | (52.80M) | (54.00M) | [{"date":"2019-12-31","value":-3669800000,"profit":false},{"date":"2020-12-31","value":-4478492100,"profit":false},{"date":"2021-12-31","value":-4416117500,"profit":false},{"date":"2022-12-31","value":-5279595500,"profit":false},{"date":"2023-12-31","value":-5400110500,"profit":false}] |
Income From Continuous Operations | (36.70M) | (44.78M) | (44.16M) | (53.01M) | (50.73M) | [{"date":"2019-12-31","value":-3669895700,"profit":false},{"date":"2020-12-31","value":-4478492100,"profit":false},{"date":"2021-12-31","value":-4416117500,"profit":false},{"date":"2022-12-31","value":-5301038200,"profit":false},{"date":"2023-12-31","value":-5073300000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (36.70M) | (44.78M) | (44.16M) | (52.80M) | (50.73M) | [{"date":"2019-12-31","value":-3669800000,"profit":false},{"date":"2020-12-31","value":-4478492100,"profit":false},{"date":"2021-12-31","value":-4416117500,"profit":false},{"date":"2022-12-31","value":-5279595500,"profit":false},{"date":"2023-12-31","value":-5073300000,"profit":false}] |
EPS (Diluted) | (1.67) | (1.56) | (1.40) | (1.50) | (1.11) | [{"date":"2019-12-31","value":-167,"profit":false},{"date":"2020-12-31","value":-156,"profit":false},{"date":"2021-12-31","value":-140,"profit":false},{"date":"2022-12-31","value":-150,"profit":false},{"date":"2023-12-31","value":-111,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
CUE | |
---|---|
Cash Ratio | 1.93 |
Current Ratio | 2.22 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
CUE | |
---|---|
ROA (LTM) | -52.11% |
ROE (LTM) | -138.87% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
CUE | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.43 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.57 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
CUE | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 7.49 |
P/B | 2.61 |
Price/FCF | NM |
EV/R | 4.54 |
EV/Ebitda | NM |
Cue Biopharma (CUE) share price today is $0.94
Yes, Indians can buy shares of Cue Biopharma (CUE) on Vested. To buy Cue Biopharma from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in CUE stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Cue Biopharma (CUE) via the Vested app. You can start investing in Cue Biopharma (CUE) with a minimum investment of $1.
You can invest in shares of Cue Biopharma (CUE) via Vested in three simple steps:
The 52-week high price of Cue Biopharma (CUE) is $3.2. The 52-week low price of Cue Biopharma (CUE) is $0.45.
The price-to-earnings (P/E) ratio of Cue Biopharma (CUE) is
The price-to-book (P/B) ratio of Cue Biopharma (CUE) is 2.61
The dividend yield of Cue Biopharma (CUE) is 0.00%
The market capitalization of Cue Biopharma (CUE) is $69.05M
The stock symbol (or ticker) of Cue Biopharma is CUE